Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.30
-0.5300-3.35%
Post-market: 15.400.1000+0.65%19:35 EDT
Volume:4.74M
Turnover:72.89M
Market Cap:3.08B
PE:-18.51
High:15.81
Open:15.81
Low:15.26
Close:15.83
52wk High:16.20
52wk Low:9.84
Shares:201.40M
Float Shares:195.63M
Volume Ratio:1.36
T/O Rate:2.42%
Dividend:1
Dividend Rate:6.54%
EPS(TTM):-0.8265
EPS(LYR):-1.4300
ROE:-4.86%
ROA:2.75%
PB:1.00
PE(LYR):-10.70

Loading ...

BRIEF-Park Hotels & Resorts Q1 Adjusted FFO Per Share USD 0.45

Reuters
·
May 01

Park Hotels & Resorts Q1 Adjusted Ffo per Share USD 0.45

THOMSON REUTERS
·
May 01

Park Hotels & Resorts Outlook FY Comparable Revpar USD 192-196

THOMSON REUTERS
·
May 01

Park Hotels & Resorts Outlook FY Adjusted Ffo per Share USD 1.74-1.9

THOMSON REUTERS
·
May 01

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

GlobeNewswire
·
Apr 30

Thirteen Individuals Detained for Orchestrating Vulgar Online Streaming "Showdown" Competitions

Deep News
·
Apr 30

Park Hotels & Resorts Inc expected to post earnings of 3 cents a share - Earnings Preview

Reuters
·
Apr 29

Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial

TIPRANKS
·
Apr 28

Park Hotels & Resorts shareholders elect nine directors at annual meeting

Reuters
·
Apr 28

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

GlobeNewswire
·
Apr 28

Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

GlobeNewswire
·
Apr 27

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

GlobeNewswire
·
Apr 27

Hilton plans 15 new hotels in Morocco to double portfolio to 25 properties

Reuters
·
Apr 24

Earning Preview: Park Hotels & Resorts Inc. this quarter’s revenue is expected to decrease by 0.21%, and institutional views are bearish

Earnings Agent
·
Apr 24

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting

GlobeNewswire
·
Apr 23

Press Release: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Dow Jones
·
Apr 23

Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform

GlobeNewswire
·
Apr 22

LUYE PHARMA's Innovative Drug LY03015 Enrolls First Patient in US Pharmacokinetic Bridging Study

Stock News
·
Apr 20

Luye Pharma Starts U.S. PK Bridging Trial for Novel CNS Drug LY03015

TIPRANKS
·
Apr 20

Comparison of Major Brokerages' Overseas Expansion: Who Leads the Pack?

Deep News
·
Apr 13